Back to School: How biopharma can reboot drug development. Access exclusive analysis here
AGIX plans to discontinue the 300 mg AGI-1067 arm of the placebo-controlled, double-blind, international
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury